Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWCH | ISIN: GB00BMC3RJ87 | Ticker-Symbol: RYH0
Frankfurt
27.06.25 | 15:29
0,147 Euro
-0,68 % -0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SAREUM HOLDINGS PLC Chart 1 Jahr
5-Tage-Chart
SAREUM HOLDINGS PLC 5-Tage-Chart

Aktuelle News zur SAREUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.06.Sareum Holdings - A decisive step towards Phase II230Sareum Holdings has reported the initiation of toxicology studies required ahead of the Phase II studies for its lead TYK2/JAK1 asset, SDC-1801. We view this as a key milestone in SDC-1801's development...
► Artikel lesen
29.05.Sareum starts toxicology studies for lead inhibitor-
29.05.Sareum Holdings PLC - Initiation of Toxicology Studies for SDC-1801-
28.04.Sareum Holdings PLC - Update on TYK2/JAK1 and SRA737 Programmes1
24.04.Sareum Holdings PLC - Exercise of Warrants1
10.04.Sareum Holdings - Broader pipeline, bigger milestones254Sareum Holdings' H125 results (to 31 December 2024) summarised a period of operational progress and an improved capital position, with successful fund-raising. Since the completion of the Phase I trial...
► Artikel lesen
27.03.Sareum-Vorsitzender erhöht Anteil durch Aktienkauf1
27.03.Sareum chairman boosts stake with share purchase3
SAREUM Aktie jetzt für 0€ handeln
27.03.Sareum Holdings PLC - Director's Dealing-
25.03.Sareum Holdings PLC - Sareum Half-Year Report-
20.03.Sareum Holdings PLC - Notice of HY Results and Investor Presentation1
14.03.Sareum Holdings - New fund-raise and licence signal active 2025383Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had previously held a 27.5% economic interest. Following this acquisition...
► Artikel lesen
13.03.Sareum Holdings PLC - Institutional Equity Fundraise-
13.03.Sareum Holdings PLC - Sareum Acquires Licence for SRA7372
31.12.24Sareum served notice on commercial licence for cancer treatment2
31.12.24Sareum shares drop on product licence termination4
31.12.24Sareum Holdings PLC - Update on SRA7371
12.11.24Sareum Holdings - SDC-1801 prepping to enter Phase II353Sareum Holdings' FY24 results summarised an active period for lead asset SDC-1801, a dual TYK2/JAK1 inhibitor, which successfully completed Phase I trials in Australia and is now undergoing preparatory...
► Artikel lesen
11.10.24Sareum Holdings - New funding extends runway to Phase II379Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial...
► Artikel lesen
02.07.24Sareum Holdings - SDC-1801 records positive Phase Ia data362Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting autoimmune conditions. The results, which include...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1